FDA Study May Proceed Notice Received for Phase II Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Therapeutics, Inc. announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the US FDA to evaluate TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin signaling, in a Phase II clinical trial for the treatment of patients with FAP.